Clinical trials: Thalidomide
Thalassemia
Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia
Thalidomide is known to have hypnosedative, immuno-modulatory and anti-angiogenic effects. The drug is widely used in several neoplastic disorders (e.g. multiple myeloma and malignant melanoma), inflammatory conditions (e.g.
- Trial name
- Thal-Thalido (NCT03651102)
- Testing
- Thalidomide and Hydroxyurea
- Where
- Pakistan
- Volunteers
- 654 people
- Sponsor
- Blood Diseases Clinic
Systemic Lupus Erythematosus (SLE), Juvenile SLE
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness.
- Conditions
- Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus
- Trial name
- NCT03122431
- Testing
- Thalidomide, Hydroxychloroquine reduced, standard dose of HCQ
- Where
- Brazil
- Volunteers
- 93 people
- Sponsor
- University of Sao Paulo General Hospital
Thalassemia, Beta
Clinical Experience of Thalidomide in Thalassemic Patients
Objectives Primary objective: To determine the efficacy and safety of the combination therapy of Hydroxyurea and thalidomide in beta-thalassemia patients.
- Trial name
- NCT05132270
- Testing
- hydroxyurea and thalidomide
- Where
- Pakistan
- Volunteers
- 135 people
- Sponsor
- Children's Hospital Karachi
HIV Infections, Stomatitis, Aphthous
Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection
PRIMARY: To evaluate the effectiveness and safety of thalidomide for treatment of oral and esophageal aphthous ulcers (those unrelated to a known infection or malignancy) in patients with advanced HIV disease.
- Trial name
- NCT00000790
- Testing
- Thalidomide
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant.
- Trial name
- NCT00075829
- Testing
- One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant
- Where
- 36 sites in United States
- Volunteers
- 710 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Crohn Disease
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
Crohn's disease (CD) is a life-long inflammatory bowel disease disease with an unknown pathogenesis. The ultimate goal of therapy is to modify the natural history of CD thus reducing complications.
- Trial name
- NCT03221166
- Testing
- Thalidomide, Infliximab
- Where
- 6 sites in Italy
- Volunteers
- 9 people
- Sponsor
- IRCCS Burlo Garofolo
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. Prednisone may be effective in preventing relapse of multiple myeloma.
- Trial name
- NCT00006890
- Testing
- prednisone, thalidomide
- Where
- 64 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- NCIC Clinical Trials Group
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized phase III trial to compare the effectiveness of tamoxifen with that of thalidomide in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer
- Trial name
- NCT00041080
- Testing
- tamoxifen citrate, thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
This phase II trial is studying how well thalidomide works in treating patients with carcinosarcoma of the uterus that has come back or that does not go to remission (decrease or disappear but may still be in the body) despite…
- Trial name
- NCT00025506
- Testing
- Laboratory Biomarker Analysis, Thalidomide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00025220
- Testing
- Thalidomide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Brain Stem Neoplasms, Primary, Neoplasms, Brain Stem
Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
Treatment on this study combines two drugs: Thalomid™ (thalidomide) and carboplatin. Thalidomide has been available for many years and has been used to treat many different illnesses.
- Trial name
- NCT00179881
- Testing
- Carboplatin, Thalomid, External Beam Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Dermatologic, Other
Expanded Access for CC-2001
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-2001.
- Trial name
- NCT03723083
- Testing
- CC-2001
- Where
- United States
- Sponsor
- Celgene
Prostate Cancer
Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
The goal of this clinical research study is to find out whether it is safe to treat patients diagnosed with locally advanced prostate cancer with the drug Thalidomide before removing the tumor (radical retropubic prostatectomy).
- Trial name
- NCT00038181
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Thalidomide-Dexamethasone for Multiple Myeloma
Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.
- Trial name
- NCT00038090
- Testing
- Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Thalidomide for Multiple Myeloma
The objective of this protocol is to assess therapeutic activity of thalidomide in previously untreated patients with asymptomatic multiple myeloma.
- Trial name
- NCT00038233
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
The three study drugs (Thalidomide, Taxol, and Estramustine) used in this study are all chemotherapy drugs used in shrinking the cancer.
- Trial name
- NCT00038246
- Testing
- Estramustine, Thalidomide, Paclitaxel (Taxol)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor.
- Trial name
- NCT00400517
- Testing
- sargramostim, thalidomide, conventional surgery
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Multiple Myeloma
Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
The purpose of this study is to determine whether the association of Thalidomide to Melphalan and Prednisone is effective in the treatment of newly diagnosed elderly multiple myeloma.
- Trial name
- NCT00232934
- Testing
- Thalidomide
- Where
- 13 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Gruppo Italiano per lo Studio del Mieloma Multiplo
Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
Thalidomide may stop the growth of soft tissue sarcoma by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
- Trial name
- NCT00089544
- Testing
- Dacarbazine, Doxorubicin Hydrochloride, Filgrastim
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
This phase II trial studies the side effects and how well giving thalidomide, dexamethasone, and clarithromycin together works in treating patients with multiple myeloma previously treated with transplant.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00182663
- Testing
- clarithromycin, thalidomide, dexamethasone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center